文献速递眼整形与眼眶神经眼科

活动性甲状腺眼病接受替妥木单抗治疗后的再活化

Reactivation After Teprotumumab Treatment for Active Thyroid Eye Disease.
PubMed 文献 · Am J Ophthalmol · 2023-12-23

该回顾性连续病例系列研究了2020年5月至2021年5月在科尔眼科研究所接受替妥木单抗治疗的活动性甲状腺眼病患者,共纳入21例。在17例初始应答者中,8例(47%)出现再活化,2例(12%)出现孤立性眼球突出回退;整个研究期间仅7/21例(33%)持续应答。最终访视时各亚组复视均无统计学显著变化(P=0.68至>.99)。

要点

  • 17例初始应答者中8例(47%)再活化,2例(12%)孤立性眼球突出回退。
  • 整个研究期间21例中仅7例(33%)持续应答。
  • 最终访视各亚组复视无统计学显著变化(P=0.68至>.99)。

核心结论

  • 最多33%的患者在替妥木单抗治疗后2年显示持续应答。
  • 80%的回退发生在疾病再活化背景下,同时伴有眼球突出和临床活动度评分回退。
  • 替妥木单抗治疗对复视的长期改善似乎很小。

研究设计与样本

  • 回顾性连续病例系列,纳入2020年5月至2021年5月在科尔眼科研究所接受替妥木单抗治疗的活动性甲状腺眼病患者,排除输注完成后随访不足6个月者,共21例。

主要发现

  • 眼球突出更严重眼在替妥木单抗治疗后平均长期改善为1.57 mm(范围-3至4 mm)。
  • 17例初始应答者中8例(47%)再活化和2例(12%)孤立性眼球突出回退;整个研究期间21例中7例(33%)持续应答。
  • 平均回退时间为12.25个月(范围2至22.5个月)。
  • 最终访视时各亚组复视无统计学显著变化(P=0.68至>.99)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To determine the recurrence and reactivation rates after teprotumumab therapy for active thyroid eye disease. DESIGN: Retrospective consecutive case series. METHODS: This was a study of all patients followed for active thyroid eye disease at the Cole Eye Institute, Cleveland Clinic, treated with teprotumumab between May 2020 and May 2021. Patients with less than 6 months follow-up after completion of infusions were excluded. The primary outcome measure was reactivation, defined as a regression in proptosis (increase of ≥2 mm in either eye and to within ≤2 mm of pre-treatment level and Clinical Activity Score [CAS] worsening of 2 points or greater). Secondary outcome was diplopia response. RESULTS: A total of 21 patients were included in the study. The average long-term improvement in proptosis in the eye with more proptosis after teprotumumab was 1.57mm (range, -3 to 4 mm). Of the 17 initial responders, there were 8 reactivations (47%) and 2 isolated proptosis regressions (12%); Overall, 7 of 21 patients (33%) responded throughout the study period. Average time to regression was 12.25 months (range, 2-22.5 months). There was no statistically significant change in diplopia at final visit in any subgroup (P = 0.68 to >.99). CONCLUSIONS: At most, 33% of patients demonstrate continued response 2 years after teprotumumab treatment. The proptosis and CAS regression occurs in the setting of disease reactivation in 80% of regressions. Teprotumumab treatment appears to offer minimal long-term improvement in diplopia.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Hwang CJ, Rebollo NP, Mechels KB, et al. Reactivation After Teprotumumab Treatment for Active Thyroid Eye Disease. Am J Ophthalmol. 2023. PMID: 38142982. doi:10.1016/j.ajo.2023.12.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。